Discover
Tecentriq (atezolizumab) / RocheTecentriq: Data from P3 IMpassion031 trial (NCT03197935) for neoadjuvant TNBC in 2020 (Roche) - Sep 17, 2019 - Pharma Day: Data from P3 IMvigor010 trial (NCT02450331) as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer in 2020 [Screenshot]Keytruda (pembrolizumab) / Merck (MSD)Keytruda clinical trial estimate: Data from P3 KEYNOTE-355 trial (NCT02819518) for 1L TNBC in early 2020 (Morgan Stanley) - Sep 20, 2019 - A subscription to Thomson ONE is required to gain full access to report 67912369; Page no: 7; REPORT TITLE: "Pharmaceuticals: Specialist prescribing dynamics: Focus on oncology”; AUTHOR: Purcell, Mark, et al; DATE: 09/05/2019Verzenio (abemaciclib) / Eli LillyLilly’s MONARCH plus study reaches primary endpoint (GBI Health) - Sep 20, 2019 - P3, N=463; MONARCH plus (NCT02763566); Sponsor: Eli Lilly and Company; “US major Eli Lilly's MONARCH plus Phase III clinical study for protease inhibitor abemaciclib has met the company's expectations. After receiving an abemaciclib treatment in combination with an aromatase inhibitor (anastrozole/letrozole) or fulvestrant, HR+/HER2- pre-menopausal advanced breast cancer Chinese female patients with tumor progression who had been previously treated with endocrine therapy saw their progression free survival (PFS) significantly prolonged, and experienced good tolerance towards the drug. Furthermore, the safety spectrum is consistent with previous clinical studies.”Tecentriq (atezolizumab) / RocheChugai obtains approval for additional indication and formulation for Tecentriq in PD-L1-positive triple negative breast cancer (Chugai Press Release) - Sep 20, 2019 - "Chugai Pharmaceutical Co., Ltd...announced...that it has obtained regulatory approval for its humanized anti-PD-L1 monoclonal antibody, Tecentriq® [generic name: atezolizumab (genetical recombination)] from the Ministry of Health, Labour and Welfare (MHLW) for an additional indication of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or metastatic breast cancer. It has also obtained approval for an additional formulation of Tecentriq 840 mg. Tecentriq 840 mg was developed to provide an optimal formulation for breast cancer for which approved dosage is 840 mg once every 2 weeks."Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer; Ibrance (palbociclib) / Pfizer; Bavencio (avelumab) / EMD Serono, Pfizer; Xtandi (enzalutamide) / Pfizer, AstellasPfizer presents scientific advancements in cancer care at the ESMO Congress 2019 highlighting expanded portfolio (Businesswire) - Sep 19, 2019 - P3, N=645; BEACON CRC (NCT02928224); Sponsor: Array BioPharma; P3, N=886; JAVELIN Renal 101 (NCT02684006); Sponsor: Pfizer; P1, N=147; NCT02573259; Sponsor: Pfizer; “Pfizer Inc….is presenting data across its industry-leading oncology portfolio, including company-sponsored and collaborative research studies, spanning 11 therapies in 22 types of cancer, at the European Society for Medical Oncology (ESMO) Congress to be held in Barcelona, Spain, September 27 - October 1, 2019. Data from nearly 50 abstracts involving Pfizer cancer medicines will illustrate the diversity of the portfolio and the company’s cutting-edge scientific approach. For the first time, this will include data presentations on compounds from the acquisition of Array Biopharma Inc.”Ibrance (palbociclib) / Pfizer; Kisqali (ribociclib) / Novartis; Verzenio (abemaciclib) / Eli LillyFDA warns against pneumonitis with CDK 4/6 inhibitor drugs for breast cancer (Korea Biomedical Review) - Sep 16, 2019 - "The U.S. Food and Drug Administration added a warning that the entire class of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor drugs for breast cancer could cause pneumonitis. However, the regulator made it clear that the medicines’ overall benefit was still greater than the risks for advanced breast cancer patients. The FDA said on Friday that Pfizer’s Ibrance (ingredient: palbociclib), Novartis’ Kisqali (ribociclib), and Lilly’s Verzenio (abemaciclib) might cause rare but severe lung inflammation in patients with advanced breast cancer."Kisqali (ribociclib) / NovartisAddition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer (Canada Newswire) - Sep 19, 2019 - "Novartis Pharmaceuticals Canada Inc... is pleased to announce that Quebec will now reimburse KISQALI® (ribociclib) for eligible patients in combination with an aromatase inhibitor (letrozole) under the province's public drug program for first-line treatment of postmenopausal women living with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.”access to treatment for metastatic breast cancer."Keytruda (pembrolizumab) / Merck (MSD); Bria-IMT (SV-BR-1-GM) / BriaCellBriaCell announces public disclosure: Remarkable responder in combination study of lead candidate with Keytruda (GlobeNewswire) - Sep 19, 2019 - P1/2a, N=40; NCT03328026; Sponsor: BriaCell Therapeutics Corporation; "The top responder...in the Combination Study experienced a highly remarkable reduction in breast cancer tumors....She showed one of the best immune responses and displayed a highly remarkable reduction in breast cancer tumors (metastases) in the adrenal gland and the outer lining of the brain...The data presented today also noted that the Bria-IMT™ regimen administered with KEYTRUDA® was safe and well tolerated. The women who showed the best clinical responses to the combination of the Bria-IMT™ regimen with KEYTRUDA® also showed the best immune responses including a cellular immune response..."Keytruda (pembrolizumab) / Merck (MSD); Bria-IMT (SV-BR-1-GM) / BriaCellBriaCell to present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia (GlobeNewswire) - Sep 16, 2019 - P1/2, N=40; NCT03328026; Sponsor: BriaCell Therapeutics Corporation; “BriaCell Therapeutics Corp….announces that the Company will be presenting at the 2nd Annual Next Gen Immuno-Oncology Congress, taking place September 19-20, 2019 at Hilton Garden Inn, Philadelphia Center City….present the latest clinical findings of the Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with pembrolizumab…”
